Go Pro
OTCMKTS:MCUJF

Medicure Q2 2024 Earnings Report

Medicure logo
$0.67 0.00 (0.00%)
As of 06/26/2026

Medicure EPS Results

Actual EPS
-$0.09
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
$3.78 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Medicure Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Medicure's next earnings date is estimated for Wednesday, August 26, 2026, based on past reporting schedules.

Conference Call Resources

Medicure Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (OTCMKTS:MCUJF) Pharmaceutical Corp. is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of therapies in the cardiovascular and critical‐care markets. The company advances its business through a combination of in-licensing, acquisitions and strategic partnerships designed to build a diversified portfolio of prescription products that address unmet medical needs.

Headquartered in Montreal, Canada, Medicure operates in North America and selectively in Europe through licensing agreements with regional distributors. Its commercial portfolio includes branded cardiovascular products, while its research and development pipeline features small‐molecule candidates targeting acute heart failure, pulmonary hypertension and related conditions. The company leverages its regulatory and clinical expertise to shepherd assets from late‐stage development through to market access.

Since its founding in 2004, Medicure has grown by forging collaborations with both larger pharmaceutical companies and specialty distributors, aiming to accelerate product launches and maximize reach in key therapeutic segments. The senior leadership team brings decades of experience in drug development, regulatory affairs and commercial operations, positioning Medicure to advance its niche cardiovascular and critical‐care medicines to patients in need.

View Medicure Profile